PMP Pals' Network
homeabout usblogmember servicessupportconferencesdiagnosticsclinical trialsnutritiontreatments
DPAMmucinous adenocarcinomaperitoneal carcinomatosissignet ring cell
pseudomyxoma peritonei & related diseasesappendix cancersurgeons & specialistssubscription membershipscontact us
PSEUDOMYXOMA PERITONEI & RELATED DISEASES
Mucinous Adenocarcinoma
Symptoms, Diagnosis and Treatment



Mucinous Adenocarcinoma of the Appendix and Pseudomyxoma Peritonei Diagnosis

Mucinous Adenocarcinoma
of the Appendix is among the most common diagnoses under the "umbrella description" of Pseudomyxoma Peritonei.

The diagnosis of Peritoneal Mucinous Carcinomatosis indicates  the presence of mucin accompanied by abundant malignant epithelium, high-grade atypia (Ronnett et al, 1995). Mucinous Carcinomatosis indicates a more challenging prognosis relative to the more common pattern of Disseminated Peritoneal Adenomucinosis aka DPAM.

Approximately 20% of appendix cancer cases are categorized as Mucinous Cystadenocarcinoma.  This type of tumor produces mucin that  eventually fills the abdominal cavity causing distension, bloating, pain, shortness of breath and interference with digestive and bowel function.

Refer to our
diagnostics page for detailed information describing laboratory and imaging testing.

The PMP Pals' Network hosts the Mucinous Adenocarcinoma of the Appendix Pals' Resource Group, comprised of patients from all over the world, who share this diagnosis.

If you are a patient, review a copy of your written pathology report and check the "final paragraph" description for the term "Mucinous Adenocarcinoma" or ask your physician to review your pathology report with you. Each patient should be given a copy of his or her own written pathology report.

View
"Pal Profiles" and photos of patients living successfully following the diagnosis of Mucinous Adenocarcinoma.

Subscribing members of the PMP Pals' Network programs are welcome to participate in the Mucinous Adenocarcinoma of the Appendix  Resource Group
.

Peritoneal Carcinomatosis Research, International   

Review an extensive series of research articles by the world's most renowned specialists in this field:

Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies:
Research from 3rd International Symposium on Peritioneal Carcinomatosis, June 2008
Source: Prof Pompiliu Piso and Colleagues


Mucinous Adenocarcinoma of the Appendix and Pseudomyxoma Peritonei Prognosis

Many factors contribute to the prognosis. These factors may include pathology, staging at the time of diagnosis, overall health of the patient at the time of the diagnosis, age at the time of diagnosis
access to specialized care, etc.

If left untreated, tumor cells and mucin can increase with time, eventually resulting in  bowel obstruction, when the areas of the abdominal cavity and pelvis normallyutilized for nutritional function and elimination, eventually become replaced by mucinous tumors.

Mucinous Adenocarcinoma of the Appendix: Prognosis for VEGF expression patients 


Analysis of Mucinous Adencarcinoma of the Appendix prognosis following "second look" surgery.
Source: Dr Paul Sugarbaker 2000

Mucinous Adenocarcinoma of the Appendix and Pseudomyxoma Peritonei Treatment

HIPEC or Hyperthermic Intraperitoneal Chemotherapy, for the treatment of Mucinous Adenocarcinoma, may be administered if complete tumor debulking is accomplished through cytoreductive surgery.

The HIPEC treatment includes the infusion of the abdominal cavity with a specific  chemotherapy, heated to approximately 40 degrees Celsius for a period of approximately 90 minutes.

The purpose of the HIPEC treatment is to attempt to kill any tumor cells which were not removed during the actual surgery process.

For an extensive listing of treatments for Mucinous Adenocarcinoma,
visit the
TREATMENTS page and the SURGERY page.
 

Treatment with CRS and HIPEC
Source: Universite de Montreal, Canada, 2009

Treatment with Adjuvant Chemotherapy
Source: World Journal of Surgical Oncology, China 2008

Refer to the HIPEC page for extensive articles regarding Appendix Cancer treatment

Clinical Trials

Click here for a listing of research studies and clinical trials


Mucinous Adenocarcinoma of the Appendix and Pseudomyxoma Peritonei Diagnosis*

Mucinous Adenocarcinoma of the Appendix Synonyms   

Mucinous Adenocarcinoma
 of the Appendix CT Images

Clinicopathologic Features

Mucinous Adenocarcinoma of the Appendix

Diagnosed with endoscopy ultrasound 

Atlas of Appendix Cancer
Source: Dr Paul H Sugarbaker

Mucinous Adenocarcinoma of the Appendix Pathlogy**

Mucinous Adenocarcinoma of the Appendix

Genetic Factors Related to Mucinous Adenocarcinoma of the Appendix

MUC2 Gene Coding

REG 4 Gene Coding


Mucinous Adenocarcinoma of the Appendix, Complications


Ureteric Obstruction

Complications, with renal effects
Source: Indian Journal of Pathology and Microbiology 2008

Mucinous  Adenocarcinoma of the Appendix, OB/GYN

Case discovered during Cesarean section delivery

Case originating with the ovary
Source: Gynecological Oncology, Japan, 2009

Case originating with the cervix and linked with HPV
Source: Croatian Journal of Medicine, 2008


Adenocarcinoma of the Colon

HIV Associated with Adenocarcinoma of the Colon
Source: Clinical Colorectal Cancer

Mucinous Adenocarcinoma, Misc, Animal Cases

Intestinal Mucinous Adenocarcinoma with Pseudomyxoma Peritonei in a Dog
Source: Journal of the American Animal Hospital Assoc, 2003

Mucinous Adenocarinoma with Peritoneal Carcinomatosis in a Lion
Source: Springerlink, 2007

Pseudomyxoma Peritonei

Click here to read specifically about Pseudomyxoma Peritonei


Tumor Grade

What does "tumor grade mean?"

“Tumor grades” distinguish tumor from what appears like normal tissue, when examined under a microscope.

The tumor grade helps physicians predict how quickly the cancer may grow.

G1: well-differentiated tumor cells
G2: moderately differentiated tumor cells
G3: poorly differentiated tumor cells
G4: undifferentiated tumor cells

See
DIAGNOSTIC TESTS for more detailed information

Tumor grading and staging
Source: NIH


Caregiving

Are you a caregiver for a loved one diagnosed with Mucinous Adenocarcinoma?

We provide many helpful resources on our
CAREGIVING page!

After Treatment is Completed; Now What?

Post Treatment Plan for Cancer Survivors
Source: Journey Forward


Mission Statement of the PMP Pals' Network
Here is our mission to serve patients and their families



This web page has been contributed by the family and friends of Jeff Beach.



Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.

Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.

The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.

We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.

Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Copyright 2010 by PMP Pals' Network/All rights reserved.